[Form 4] Nuvation Bio Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nuvation Bio CFO Philippe Sauvage reported two insider purchase transactions of Class A Common Stock:

• On June 16, 2025: Acquired 3,300 shares at $1.835 per share
• On June 17, 2025: Acquired 4,000 shares at $1.79 per share

Following these transactions, Sauvage's direct ownership increased to 9,902 shares. The filing notes that his holdings include 2,602 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. These insider purchases by the CFO, totaling 7,300 shares over two consecutive days, may signal management's confidence in the company's valuation and future prospects.

Positive

• CFO Philippe Sauvage demonstrates confidence through open market purchases totaling 7,300 shares at an average price of ~$1.81, increasing direct holdings by 124% from 2,602 to 9,902 shares

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sauvage Philippe

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		P		3,300	A	$1.835	5,902(1)	D
Class A Common Stock	06/17/2025		P		4,000	A	$1.79	9,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 2,602 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Stephen Dang, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of NUVB stock did CFO Philippe Sauvage purchase in June 2025?

CFO Philippe Sauvage purchased a total of 7,300 shares of NUVB Class A Common Stock across two transactions: 3,300 shares at $1.835 per share on June 16, 2025, and 4,000 shares at $1.79 per share on June 17, 2025.

What is the total value of NUVB shares purchased by CFO Sauvage in June 2025?

The total value of shares purchased by CFO Sauvage was approximately $13,215.50 (3,300 shares × $1.835 = $6,055.50 plus 4,000 shares × $1.79 = $7,160).

How many NUVB shares does Philippe Sauvage own after these transactions?

Following these transactions, Philippe Sauvage directly owns 9,902 shares of NUVB Class A Common Stock. This includes the newly purchased shares and 2,602 shares previously acquired through the company's 2021 Employee Stock Purchase Plan in May 2025.

What is Philippe Sauvage's position at NUVB?

Philippe Sauvage serves as the Chief Financial Officer (CFO) of Nuvation Bio Inc. (NUVB).